RE:RE:RE:Pfizer Pfizer executives last week said that their antibody drug conjugate (ADC) Padcev had “mega-blockbuster” potential, which the company defines as raking in annual sales of more than $3 billion.
In December 2023 Pfizer's Padcev was approved in combination with the immune checkpoint inhibitor Keytruda for the treatment of Advanced Bladder Cancer.
https://www.pfizer.com/news/press-release/press-release-detail/padcevr-enfortumab-vedotin-ejfv-keytrudar-pembrolizumab
In 2004 research work demonstrated that intravesical administered reovirus was effective in superficial bladder cancer.
https://experts.mcmaster.ca/display/publication1636740
In February 2024 CG Oncology announced that it had dosed the first patient in a Phase 3 clinical trial in superficial (non-muscle invasive) bladder cancer involving its intravessically administered OV in combination with Keytruda - after the company went public in January 2024, and subsequent to announcing Phase 2 data in May 2023. CG Oncology's closing share price on Thursday was US$43.90 p/s.
https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-first-patient-dosed-pivot-006-phase-3-0
Given that Pfizer's ADC + Keytruda was approved in Advanced/Metastatic Bladder Cancer - their next logical step is to combine this combination with ONCY's pelareorep to enhance the I/O doublet's effectiveness and address the issue of T-cell exhaustion that happens with this ADC + Keytruda doublet combination.
CG Oncology's intravesical administration cannot treat advanced/metastatic (MUSCLE INVASIVE) bladder cancer.